Targeted Therapy: 720 Real Stories

720 stories match targeted therapy. 488 of them mention chemotherapy.

A patient, who was diagnosed with Invasive Ductal CarcinomaBreast Cancer

HER2-positive left breast cancer treated with trastuzumab and mastectomy

Patient Info: Anonymized, Female, 60s | Stage Metastatic/Advanced

Biomarkers: ER-negative; PR-negative; HER2/CerbB2 strongly positive; BRCA1/2 negative for known pathogenic variants; FANCA variant of uncertain significance.

She remained alive, asymptomatic, and disease-free while undergoing annual surveillance after treatment for the left HER2-positive breast cancer.

PubMed Central
OutcomeCancer-Free / NED
A patient, who was diagnosed with Stage IV Colorectal CancerColorectal Cancer

Severe immune thrombocytopenia during treatment for metastatic colon cancer

Patient Info: Anonymized, Female, 50s | Stage IV

Biomarkers: KRAS-mutated; microsatellite stable; BRAF-wild type.

Metastatic Site: bilateral ovaries; pelvis; peritoneum; mesenteric…

After multiple metastatic recurrences and treatment changes, she died from progressive colon cancer; oxaliplatin had been permanently stopped after antibody-confirmed immune thrombocytopenia.

PubMed Central
OutcomeIn Memory
A patient, who was diagnosed with Stage IV Colorectal AdenocarcinomaColorectal Cancer

Bilateral adrenal bleeding during bevacizumab treatment for metastatic colon cancer

Patient Info: Anonymized, Male, 50s | Stage IV

Biomarkers: RAS-mutant; BRAF-wild type; microsatellite stable.

Metastatic Site: peritoneum; liver; lung

Despite multiple systemic and local treatments, his metastatic colon cancer progressed in the liver and peritoneum, and he died from disease progression in November 2018.

PubMed Central
OutcomeIn Memory
A patient, who was diagnosed with Stage IV Gastric AdenocarcinomaGastric Cancer

Ramucirumab and paclitaxel for metastatic gastric cancer in a patient receiving hemodialysis

Patient Info: Anonymized, male, 60s | Stage IV

Biomarkers: HER2-negative

Metastatic Site: liver, distant lymph nodes

After about 16 months of disease control on paclitaxel plus ramucirumab, multiple liver metastases and distant lymph nodes progressed. Third-line irinotecan was stopped after severe toxicity, and supportive care followed.

PubMed Central
OutcomeSetback / Progression
Lee, who was diagnosed with Stage IV Colorectal CancerColorectal Cancer

Stage IV Colorectal Cancer: Lee's Survivor Story

Patient Info: Lee Jones, Male, 50s | Stage IV

Metastatic Site: Liver

As of February 2021, Lee reported no evidence of colon cancer since 2011 after treatment for Stage IV colon cancer with liver metastases, recurrence, chemotherapy, colon surgery, and liver surgery.

The Patient Story
OutcomeCancer-Free / NED
A patient, who was diagnosed with Stage IV Ovarian AdenocarcinomaOvarian Cancer

Kidney Complications After Treatment for Stage IV Ovarian Cancer

Patient Info: Anonymized, Female, 60s | Stage IV

Metastatic Site: peritoneum|left lymph node

No further ovarian-cancer progression was observed during the 10 months after kidney biopsy. The nephrotic syndrome reached partial remission after immunosuppressive treatment was stopped and supportive care continued.

PubMed Central
OutcomeStable Disease
A patient, who was diagnosed with Stage IV Lung AdenocarcinomaLung Cancer

A regressed choroidal metastasis during EGFR-targeted lung cancer treatment

Patient Info: Anonymized, Female, 40s | Stage IV

Biomarkers: EGFR exon 19 deletion.

Metastatic Site: liver; bone; central nervous system; right choroid

The right choroidal metastasis appeared inactive and regressed during systemic treatment, visual acuity remained 20/20, and no local eye treatment was required.

PubMed Central
OutcomeResponding Well
A patient, who was diagnosed with Stage IV Invasive Ductal CarcinomaBreast Cancer

A durable response to trastuzumab in heavily pretreated metastatic breast cancer

Patient Info: Anonymized, Female, 60s | Stage IV

Biomarkers: Initial tumor ER-positive and PR-positive. Metastatic liver biopsy ER-negative and PR-negative with HER2 IHC 1+ and nonamplified. Later biopsy ER and PR weakly positive at 5%–10%, HER2 IHC 1+ and nonamplified, and ERBB3 p. with evidence of HER2/HER3 pathway activation.

Metastatic Site: lungs; hilar and mediastinal lymph nodes; liver; bone

She had ongoing benefit for more than 10 months on trastuzumab and capecitabine, with improved symptoms, lower tumor markers, and a confirmed partial response.

PubMed Central
OutcomeResponding Well
Onagh, who was diagnosed with Stage III Breast CancerBreast Cancer

Stage III Breast Cancer: Onagh's Survivor Story

Patient Info: Onagh, Female | Stage III

Her stage 3 breast cancer was in complete remission, and she no longer required treatment.

Our Cancer Stories
OutcomeCancer-Free / NED
Beth, who was diagnosed with Stage III Breast CancerBreast Cancer

Stage III Breast Cancer: Beth's Survivor Story

Patient Info: Beth, Female, 40s | Stage III

As of 2021, Beth was in remission and no longer taking cancer medication after mastectomy, lymphadenectomy, chemotherapy, radiation therapy, and targeted therapy.

Our Cancer Stories
OutcomeCancer-Free / NED
Betty, who was diagnosed with Stage I Breast CancerBreast Cancer

Stage I HER2-Positive Breast Cancer: Betty's Survivor Story

Patient Info: Betty, Female, 50s | Stage I

Biomarkers: HER2-positive

As of 2021, Betty was in remission after mastectomy and chemotherapy with Herceptin, while managing side effects such as hair loss, peripheral neuropathy, and weight changes.

Our Cancer Stories
OutcomeCancer-Free / NED
Erika, who was diagnosed with Stage II Breast CancerBreast Cancer

Stage II Breast Cancer: Erika's Patient Story

Patient Info: Erika, Female, 40s | Stage II

As of 2021, Erika was undergoing treatment for Stage II breast cancer and was on targeted therapy after mastectomy, lymphadenectomy, chemotherapy, and targeted therapy.

Our Cancer Stories
OutcomeCare Ongoing
Faith, who was diagnosed with Stage II Breast CancerBreast Cancer

Stage II HR-Positive Breast Cancer: Faith's Survivor Story

Patient Info: Faith, Female, Under 40 | Stage II

Biomarkers: ER-positive; HER2-positive

Faith moved into survivorship after treatment for Stage II ER-positive, HER2-positive breast cancer, with ongoing fear of recurrence but renewed focus on family, nutrition, exercise, and work.

Our Cancer Stories
OutcomeSurvivorship / Completed Treatment
Kyle, who was diagnosed with Stage IV Colorectal AdenocarcinomaColorectal Cancer

Stage IV Colorectal Adenocarcinoma: Kyle's Survivor Story

Patient Info: Kyle, Under 40 | Stage IV

Kyle was 19 months NED and off treatment after Stage IV colon adenocarcinoma, following about 30 months of chemotherapy and targeted therapy.

Our Cancer Stories
OutcomeCancer-Free / NED
Amanda, who was diagnosed with Stage IV Colorectal AdenocarcinomaColorectal Cancer

Stage IV Colorectal Adenocarcinoma: Amanda's Patient Story

Patient Info: Amanda, Under 40 | Stage IV

She remains on ongoing treatment for Stage IV disease and describes the cancer as pretty stable while maintaining a good quality of life.

Our Cancer Stories
OutcomeStable Disease
A patient, who was diagnosed with Lung AdenocarcinomaLung Cancer

NRG1-Fusion Lung Cancer With a 24-Month Response to Afatinib

Patient Info: Anonymized, Female, 50s | Stage Metastatic/Advanced

Biomarkers: NRG1 fusion; KRAS/EGFR/ALK/ROS1/ERBB2 alterations not detected

Metastatic Site: left lung

Her cancer progressed during atezolizumab, and she died in May 2019.

PubMed Central
OutcomeIn Memory
Hwee, who was diagnosed with Stage II Breast CancerBreast Cancer

Stage II Breast Cancer: Hwee's Patient Story

Patient Info: Hwee Lin, Female, 60s | Stage II

Hwee Lin was receiving targeted therapy for Stage II breast cancer and described the treatment as effective while managing fatigue, hair loss, nausea, and vomiting with medication and improved nutrition.

Our Cancer Stories
OutcomeResponding Well
Andy, who was diagnosed with Stage II Gastric CancerGastric Cancer

Stage II Gastric Cancer: Andy's Patient Story

Patient Info: Andy | Stage II

Andy was still undergoing treatment and reported that targeted therapy was the current treatment.

Our Cancer Stories
OutcomeCare Ongoing
A patient, who was diagnosed with Lung AdenocarcinomaLung Cancer

Metastatic NRG1-Fusion Lung Cancer Responding to Long-Term Afatinib

Patient Info: Anonymized, Female, 60s | Stage Metastatic/Advanced

Biomarkers: CD74-NRG1 fusion

Metastatic Site: lungs

As of February 2020, she remained on afatinib 30 mg daily with an ongoing partial response after 27 months.

PubMed Central
OutcomeResponding Well
Kelsey, who was diagnosed with Stage II Breast CancerBreast Cancer

Stage II HER2-Positive Breast Cancer: Kelsey's Survivor Story

Patient Info: Kelsey, Female, 40s | Stage II

Biomarkers: HER2-positive

Kelsey survived Stage II HER2-positive breast cancer after mastectomy, chemotherapy, and targeted therapy, with recovery supported by nutrition changes, massages, supplements, and support-group connection.

Our Cancer Stories
OutcomeSurvivorship / Completed Treatment